美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD

49.98

+0.97031.98%

成交量：21.31萬

成交額：1,067.15萬

市值：35.64億

市盈率：-16.06

高：51.02

開：49.65

低：49.60

收：49.01

52周最高：94.90

52周最低：18.26

股本：7,130.99萬

流通股本：5,464.19萬

量比：0.50

換手率：0.39%

股息：- -

股息率：- -

每股收益(TTM):-3.1128

每股收益(LYR):-2.3852

淨資產收益率：-20.21%

總資產收益率：-14.95%

市淨率：2.63

市盈率(LYR):-20.95

資料載入中...

總覽公司新聞資訊公告

新聞稿：Septerna任命資深行業專家Rajiv Patni醫學博士擔任首席醫療官

數據簡報-隨着小型企業不斷湧現，減肥藥的上市競爭日益白熱化

晶泰控股(02228)與國際知名藥企達成超4億美元AI藥物發現戰略合作攻堅GPCR靶點口服新藥

Structure實驗性減肥藥未顯示肝損傷跡象

Structure Therapeutics宣佈，Aleniglipron在2B期試驗中顯示出長達36周以上最高達16.2%的減重效果

Structure Therapeutics旗下阿倫利普隆展現良好耐受性，停藥率僅為10.4%

Structure Therapeutics修訂並重述與Leerink Partners及Cantor Fitzgerald的銷售協議

Structure Therapeutics將ATM增發規模擴大1.5億美元總額達4億美元

埃諾格魯肽注射液全國首批處方落地

经济参考网

Structure Therapeutics任命Matthew Lang為首席運營官兼總法律顧問

BUZZ-H.C. Wainwright表示，禮來肥胖藥獲批為Structure公司的藥物創造了機會

美股異動 | 禮來(LLY.US)跌超4% 碩迪生物(GPCR.US)實驗性減肥藥公布積極數據

Structure肥胖藥物研究結果直追諾和諾德與禮來

Structure Therapeutics股價上漲6% 公布實驗性肥胖症藥物中期試驗結果

Structure Therapeutics股價逆轉走勢披露中期試驗結果後盤前大漲13.5%

Structure Therapeutics盤前跌1.6% 披露實驗性減肥藥中期試驗結果

研究顯示，結構公司的肥胖藥片最多可減輕 16.3% 的體重

Structure Therapeutics公司：FDA二期結束會議定於2026年第二季度；三期試驗啓動計劃於2026年下半年推進

Structure Therapeutics中期數據：2.5毫克起始劑量組不良事件相關停藥率為2.0%-3.4%

Structure Therapeutics公布每日一次口服小分子GLP-1受體激動劑Aleniglipron二期臨床試驗積極頂線數據

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/hant/stock/GPCR/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"GPCR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GPCR\",,,,,undefined,":{"symbol":"GPCR","market":"US","secType":"STK","nameCN":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","latestPrice":49.9803,"timestamp":1787676263276,"preClose":49.01,"halted":0,"volume":213121,"delay":0,"changeRate":0.01979800040808002,"floatShares":54641899,"shares":71309857,"eps":-3.1128,"marketStatus":"交易中","change":0.9703,"latestTime":"08-25 12:44:29 EDT","open":49.65,"high":51.02,"low":49.595,"amount":10671528.97823,"amplitude":0.029076,"askPrice":49.99,"askSize":251,"bidPrice":49.84,"bidSize":9,"shortable":3,"etf":0,"ttmEps":-3.1128,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1787688000000},"marketStatusCode":2,"adr":0,"adrRate":3,"listingDate":1675400400000,"exchange":"NASDAQ","adjPreClose":49.01,"preHourTrading":{"tag":"盘前","latestPrice":49.94,"preClose":49.01,"latestTime":"09:29 EDT","volume":700,"amount":34528.7474,"timestamp":1787664592790,"change":0.93,"changeRate":0.018976,"amplitude":0.076719},"postHourTrading":{"tag":"盘后","latestPrice":49.01,"preClose":49.01,"latestTime":"19:30 EDT","volume":147535,"amount":7230674.75,"timestamp":1787614206972,"change":0,"changeRate":0,"amplitude":0.002244},"volumeRatio":0.502472,"impliedVol":0.8951,"impliedVolPercentile":0.7968},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GPCR\",,,,,undefined,":{"symbol":"GPCR","floatShares":54641899,"roa":"-14.95%","roe":"-20.21%","lyrEps":-2.385222,"volumeRatio":0.502472,"shares":71309857,"dividePrice":0,"high":51.02,"amplitude":0.029076,"preClose":49.01,"low":49.595,"week52Low":18.264,"pbRate":"2.63","week52High":94.9,"institutionHeld":0,"latestPrice":49.9803,"committee":-0.930769,"eps":-3.1128,"divideRate":0,"volume":213121,"delay":0,"ttmEps":-3.1128,"open":49.65,"prevYearClose":69.55,"prevWeekClose":49.09,"prevMonthClose":48.04,"prevQuarterClose":53.67,"fiveDayClose":53.53,"twentyDayClose":47.89,"sixtyDayClose":39.34},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GPCR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"GPCR","fiscalQuarterEnding":"2026/06","expectedEps":-0.39,"name":null,"time":"盤後","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"post","actualEps":-0.49},{"market":"US","date":"2026-05-07","symbol":"GPCR","fiscalQuarterEnding":"2026/03","expectedEps":-0.39,"name":null,"time":"盤後","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"post","actualEps":-0.35},{"market":"US","date":"2026-02-26","symbol":"GPCR","fiscalQuarterEnding":"2025/12","expectedEps":-0.35,"name":null,"time":"盤後","type":"earning","dateTimestamp":1772082000000,"reportTimeType":"post","actualEps":-0.49},{"market":"US","date":"2025-11-06","symbol":"GPCR","fiscalQuarterEnding":"2025/09","expectedEps":-0.36,"name":null,"time":"盤後","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"post","actualEps":-0.37},{"market":"US","date":"2025-08-06","symbol":"GPCR","fiscalQuarterEnding":"2025/06","expectedEps":-0.28,"name":null,"time":"盤後","type":"earning","dateTimestamp":1754452800000,"reportTimeType":"post","actualEps":-0.36}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GPCR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GPCR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3529,"buy":0.5882,"hold":0.0588,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5882,"analysts":17,"updateTime":1777521600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GPCR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GPCR","date":"2026-08-24","current":-16.05789,"percent":0.692042,"low":-50.180001,"twenty":-24.42179,"median":-19.852578,"eighty":-10.572245,"high":-5.211405,"avg":-19.429081,"sd":8.242715,"marketCap":3500600880},"quantilePoints":[{"date":"2023-02-03","current":-25.001825,"twenty":-43.272389,"median":-43.272389,"eighty":-32.310051,"marketCap":951294422},{"date":"2023-02-10","current":-22.116999,"twenty":-35.964163,"median":-23.496907,"eighty":-22.21316,"marketCap":841529681},{"date":"2023-02-17","current":-21.285207,"twenty":-24.521021,"median":-22.645883,"eighty":-21.915061,"marketCap":809880847},{"date":"2023-02-24","current":-23.36709,"twenty":-23.715192,"median":-22.645883,"eighty":-21.847749,"marketCap":889094402},{"date":"2023-03-03","current":-25.530709,"twenty":-24.422936,"median":-22.718004,"eighty":-21.972757,"marketCap":971417957},{"date":"2023-03-10","current":-22.636267,"twenty":-24.85566,"median":-22.790125,"eighty":-22.063149,"marketCap":861287334},{"date":"2023-03-17","current":-22.232392,"twenty":-24.422936,"median":-22.70358,"eighty":-22.09392,"marketCap":845920270},{"date":"2023-03-24","current":-21.876596,"twenty":-23.762311,"median":-22.568955,"eighty":-21.891982,"marketCap":832382619},{"date":"2023-03-31","current":-16.960589,"twenty":-23.565181,"median":-22.314128,"eighty":-21.634271,"marketCap":870434396},{"date":"2023-04-06","current":-17.823234,"twenty":-23.376706,"median":-22.232392,"eighty":-21.285207,"marketCap":914706175},{"date":"2023-04-14","current":-17.473898,"twenty":-23.36709,"median":-22.116999,"eighty":-18.643102,"marketCap":896777933},{"date":"2023-04-21","current":-17.210114,"twenty":-23.194,"median":-22.059302,"eighty":-17.623613,"marketCap":883240282},{"date":"2023-04-28","current":-17.815518,"twenty":-23.078607,"median":-21.876596,"eighty":-17.586227,"marketCap":914310203},{"date":"2023-05-05","current":-17.709107,"twenty":-22.982446,"median":-21.689083,"eighty":-17.623613,"marketCap":908849077},{"date":"2023-05-12","current":-17.00755,"twenty":-22.790125,"median":-21.491953,"eighty":-17.586227,"marketCap":956079400},{"date":"2023-05-19","current":-15.32957,"twenty":-22.780509,"median":-20.818827,"eighty":-17.473898,"marketCap":861751761},{"date":"2023-05-26","current":-19.808636,"twenty":-22.761276,"median":-19.808636,"eighty":-17.466769,"marketCap":1113542462},{"date":"2023-06-02","current":-21.830342,"twenty":-22.668962,"median":-20.674586,"eighty":-17.472472,"marketCap":1227192672},{"date":"2023-06-09","current":-23.110075,"twenty":-22.668962,"median":-21.38858,"eighty":-17.563702,"marketCap":1299132872},{"date":"2023-06-16","current":-21.061141,"twenty":-22.668962,"median":-21.491953,"eighty":-17.586212,"marketCap":1183952020},{"date":"2023-06-23","current":-21.782692,"twenty":-22.640113,"median":-21.568882,"eighty":-17.608538,"marketCap":1224514048},{"date":"2023-06-30","current":-27.561913,"twenty":-22.772816,"median":-21.571672,"eighty":-17.623492,"marketCap":1549392931},{"date":"2023-07-07","current":-24.451072,"twenty":-23.059375,"median":-21.612515,"eighty":-17.625039,"marketCap":1374517018},{"date":"2023-07-14","current":-21.428724,"twenty":-23.103781,"median":-21.707815,"eighty":-17.644282,"marketCap":1204615694},{"date":"2023-07-21","current":-23.069233,"twenty":-23.103781,"median":-21.780436,"eighty":-17.700571,"marketCap":1296836908},{"date":"2023-07-28","current":-23.552536,"twenty":-23.333385,"median":-21.782692,"eighty":-17.727736,"marketCap":1324005814},{"date":"2023-08-04","current":-21.592094,"twenty":-23.51737,"median":-21.782692,"eighty":-17.804907,"marketCap":1213799550},{"date":"2023-08-11","current":-19.978813,"twenty":-23.374783,"median":-21.781564,"eighty":-17.817061,"marketCap":1123108978},{"date":"2023-08-18","current":-16.072919,"twenty":-23.333385,"median":-21.735043,"eighty":-17.644282,"marketCap":1053531639},{"date":"2023-08-25","current":-16.66259,"twenty":-23.197654,"median":-21.646551,"eighty":-17.586168,"marketCap":1092182818},{"date":"2023-09-01","current":-16.458249,"twenty":-23.185384,"median":-21.592094,"eighty":-17.468195,"marketCap":1078788845},{"date":"2023-09-08","current":-16.680105,"twenty":-23.150918,"median":-21.568882,"eighty":-17.319402,"marketCap":1093330873},{"date":"2023-09-15","current":-18.326514,"twenty":-23.110075,"median":-21.460338,"eighty":-17.211393,"marketCap":1201248026},{"date":"2023-09-22","current":-19.937893,"twenty":-23.078607,"median":-21.067948,"eighty":-17.309925,"marketCap":1306869070},{"date":"2023-09-29","current":-21.876218,"twenty":-23.069233,"median":-21.012104,"eighty":-17.319402,"marketCap":1433920470},{"date":"2023-10-06","current":-37.165618,"twenty":-23.194,"median":-21.285207,"eighty":-17.395476,"marketCap":2436094784},{"date":"2023-10-13","current":-44.162453,"twenty":-23.552536,"median":-21.525005,"eighty":-17.459473,"marketCap":2894716299},{"date":"2023-10-20","current":-45.222784,"twenty":-23.852048,"median":-21.571672,"eighty":-17.466769,"marketCap":2964217822},{"date":"2023-10-27","current":-47.275909,"twenty":-23.892891,"median":-21.592094,"eighty":-17.469621,"marketCap":3098794020},{"date":"2023-11-03","current":-48.538851,"twenty":-24.328544,"median":-21.646551,"eighty":-17.490333,"marketCap":3181576088},{"date":"2023-11-10","current":-38.273225,"twenty":-24.864943,"median":-21.735043,"eighty":-17.514986,"marketCap":2508695101},{"date":"2023-11-17","current":-27.570058,"twenty":-25.04304,"median":-21.781564,"eighty":-17.543453,"marketCap":2122673903},{"date":"2023-11-24","current":-32.691508,"twenty":-27.365869,"median":-21.782692,"eighty":-17.586168,"marketCap":2516984612},{"date":"2023-12-01","current":-35.337541,"twenty":-28.3175,"median":-21.830342,"eighty":-17.593664,"marketCap":2720707940},{"date":"2023-12-08","current":-37.983573,"twenty":-33.138225,"median":-21.904522,"eighty":-17.623452,"marketCap":2924431267},{"date":"2023-12-15","current":-37.177707,"twenty":-34.105722,"median":-22.049686,"eighty":-17.625039,"marketCap":2862386033},{"date":"2023-12-22","current":-20.939825,"twenty":-34.105722,"median":-22.001606,"eighty":-17.644282,"marketCap":1612198995},{"date":"2023-12-29","current":-23.446258,"twenty":-34.065552,"median":-22.068918,"eighty":-17.684898,"marketCap":1805174329},{"date":"2024-01-05","current":-26.187472,"twenty":-34.000259,"median":-22.102574,"eighty":-17.702705,"marketCap":2016225834},{"date":"2024-01-12","current":-28.789086,"twenty":-33.67371,"median":-22.232392,"eighty":-17.746366,"marketCap":2216529345},{"date":"2024-01-19","current":-27.710368,"twenty":-33.290514,"median":-22.259189,"eighty":-17.804907,"marketCap":2133476670},{"date":"2024-01-26","current":-26.745867,"twenty":-33.138225,"median":-22.283013,"eighty":-17.817061,"marketCap":2059217807},{"date":"2024-02-02","current":-28.598724,"twenty":-32.691508,"median":-22.44298,"eighty":-17.823234,"marketCap":2201872991},{"date":"2024-02-09","current":-29.823387,"twenty":-32.667396,"median":-22.576119,"eighty":-17.835432,"marketCap":2296162205},{"date":"2024-02-16","current":-28.427399,"twenty":-32.293017,"median":-22.636267,"eighty":-17.890184,"marketCap":2188682272},{"date":"2024-02-23","current":-26.035182,"twenty":-31.181303,"median":-22.647193,"eighty":-17.91403,"marketCap":2004500750},{"date":"2024-03-01","current":-25.743294,"twenty":-31.092467,"median":-22.775115,"eighty":-17.959972,"marketCap":1982027673},{"date":"2024-03-08","current":-22.849791,"twenty":-30.933832,"median":-22.849791,"eighty":-18.031985,"marketCap":1759251085},{"date":"2024-03-15","current":-18.291889,"twenty":-29.823387,"median":-22.775115,"eighty":-18.031985,"marketCap":1639319082},{"date":"2024-03-22","current":-22.815466,"twenty":-29.601298,"median":-22.761276,"eighty":-18.070517,"marketCap":2044722039},{"date":"2024-03-28","current":-22.311113,"twenty":-29.398245,"median":-22.645883,"eighty":-18.070517,"marketCap":1999521939},{"date":"2024-04-05","current":-20.434088,"twenty":-29.301795,"median":-22.601624,"eighty":-18.089549,"marketCap":1831303011},{"date":"2024-04-12","current":-20.928042,"twenty":-29.107626,"median":-22.568955,"eighty":-18.098906,"marketCap":1875571150},{"date":"2024-04-19","current":-18.81184,"twenty":-29.061939,"median":-22.455039,"eighty":-18.224405,"marketCap":1685917123},{"date":"2024-04-26","current":-20.267704,"twenty":-28.863962,"median":-22.311113,"eighty":-18.256547,"marketCap":1816391638},{"date":"2024-05-03","current":-20.281918,"twenty":-28.794162,"median":-22.289169,"eighty":-18.270537,"marketCap":1817665530},{"date":"2024-05-10","current":-20.105056,"twenty":-28.789086,"median":-22.270856,"eighty":-18.288305,"marketCap":1801815151},{"date":"2024-05-17","current":-17.123915,"twenty":-28.636796,"median":-22.232392,"eighty":-18.098906,"marketCap":1672681180},{"date":"2024-05-24","current":-18.288418,"twenty":-28.476893,"median":-22.116999,"eighty":-18.062811,"marketCap":1786430959},{"date":"2024-05-31","current":-16.11295,"twenty":-28.435013,"median":-22.068918,"eighty":-17.902107,"marketCap":1573929112},{"date":"2024-06-07","current":-26.55105,"twenty":-28.381712,"median":-22.102574,"eighty":-17.902107,"marketCap":2593533072},{"date":"2024-06-14","current":-24.646705,"twenty":-28.337752,"median":-22.198735,"eighty":-17.932407,"marketCap":2407514791},{"date":"2024-06-21","current":-22.312809,"twenty":-28.3175,"median":-22.24579,"eighty":-17.974375,"marketCap":2179537500},{"date":"2024-06-28","current":-18.680713,"twenty":-28.3175,"median":-22.24579,"eighty":-18.00318,"marketCap":1824750754},{"date":"2024-07-05","current":-17.874111,"twenty":-28.267548,"median":-22.198735,"eighty":-17.932407,"marketCap":1745961056},{"date":"2024-07-12","current":-20.408464,"twenty":-28.068249,"median":-22.08815,"eighty":-17.932407,"marketCap":1993519219},{"date":"2024-07-15","current":-20.943017,"twenty":-28.006064,"median":-22.078534,"eighty":-17.941595,"marketCap":2045734877},{"date":"2024-08-02","current":-17.387286,"twenty":-27.943879,"median":-22.068918,"eighty":-17.908069,"marketCap":1698407510},{"date":"2024-08-09","current":-16.461364,"twenty":-27.802578,"median":-21.942986,"eighty":-17.823234,"marketCap":1607962532},{"date":"2024-08-16","current":-20.792004,"twenty":-27.780694,"median":-21.876596,"eighty":-17.821691,"marketCap":2088244945},{"date":"2024-08-23","current":-22.295452,"twenty":-27.74971,"median":-21.929398,"eighty":-17.823234,"marketCap":2239243758},{"date":"2024-08-30","current":-21.822777,"twenty":-27.716713,"median":-21.953525,"eighty":-17.863936,"marketCap":2191770646},{"date":"2024-09-06","current":-21.851252,"twenty":-27.691332,"median":-21.926349,"eighty":-17.874111,"marketCap":2194630472},{"date":"2024-09-13","current":-22.944669,"twenty":-27.671026,"median":-21.901472,"eighty":-17.880178,"marketCap":2304447790},{"date":"2024-09-20","current":-22.067657,"twenty":-27.608415,"median":-21.926349,"eighty":-17.902107,"marketCap":2216365150},{"date":"2024-09-27","current":-23.650834,"twenty":-27.565171,"median":-22.001606,"eighty":-17.941595,"marketCap":2375371475},{"date":"2024-10-04","current":-24.083644,"twenty":-27.536769,"median":-22.068918,"eighty":-18.000093,"marketCap":2418840830},{"date":"2024-10-11","current":-22.130301,"twenty":-27.481934,"median":-22.12365,"eighty":-18.029927,"marketCap":2222656767},{"date":"2024-10-18","current":-22.563112,"twenty":-27.163394,"median":-22.116999,"eighty":-18.055104,"marketCap":2266126122},{"date":"2024-10-25","current":-21.333018,"twenty":-26.967956,"median":-22.11226,"eighty":-18.070517,"marketCap":2142581639},{"date":"2024-10-31","current":-21.560813,"twenty":-26.932422,"median":-22.097835,"eighty":-18.080033,"marketCap":2165460247},{"date":"2024-11-08","current":-21.839862,"twenty":-26.875803,"median":-22.107521,"eighty":-18.096607,"marketCap":2193486542},{"date":"2024-11-15","current":-19.500107,"twenty":-26.820843,"median":-22.068288,"eighty":-18.16223,"marketCap":2155736838},{"date":"2024-11-22","current":-15.573182,"twenty":-26.740791,"median":-22.039183,"eighty":-18.047398,"marketCap":1721615252},{"date":"2024-11-29","current":-17.170432,"twenty":-26.702879,"median":-21.932448,"eighty":-17.923218,"marketCap":1898191276},{"date":"2024-12-06","current":-16.181125,"twenty":-26.575564,"median":-21.883856,"eighty":-17.833409,"marketCap":1788823393},{"date":"2024-12-13","current":-16.424567,"twenty":-26.524021,"median":-21.851252,"eighty":-17.817061,"marketCap":1815735909},{"date":"2024-12-20","current":-15.523314,"twenty":-26.386717,"median":-21.835102,"eighty":-17.715324,"marketCap":1716102339},{"date":"2024-12-27","current":-15.30059,"twenty":-26.269962,"median":-21.822777,"eighty":-17.687076,"marketCap":1691480250},{"date":"2025-01-03","current":-14.601342,"twenty":-26.20397,"median":-21.78933,"eighty":-17.625803,"marketCap":1614178343},{"date":"2025-01-10","current":-14.005686,"twenty":-26.17605,"median":-21.782692,"eighty":-17.604018,"marketCap":1548328570},{"date":"2025-01-17","current":-13.974608,"twenty":-26.160821,"median":-21.780436,"eighty":-17.514986,"marketCap":1544892930},{"date":"2025-01-24","current":-14.482211,"twenty":-26.10752,"median":-21.737354,"eighty":-17.469621,"marketCap":1601008389},{"date":"2025-01-31","current":-15.7046,"twenty":-26.035182,"median":-21.700984,"eighty":-17.381485,"marketCap":1736143575},{"date":"2025-02-07","current":-15.549212,"twenty":-26.032644,"median":-21.680405,"eighty":-17.295679,"marketCap":1718965373},{"date":"2025-02-14","current":-12.622728,"twenty":-25.9819,"median":-21.605123,"eighty":-17.234446,"marketCap":1395442576},{"date":"2025-02-21","current":-12.115125,"twenty":-25.903236,"median":-21.581883,"eighty":-17.21037,"marketCap":1339327118},{"date":"2025-02-28","current":-11.819887,"twenty":-25.84482,"median":-21.567582,"eighty":-17.171628,"marketCap":1306688535},{"date":"2025-03-07","current":-11.01217,"twenty":-25.735679,"median":-21.559435,"eighty":-17.124089,"marketCap":1349277189},{"date":"2025-03-14","current":-9.547313,"twenty":-25.689992,"median":-21.491953,"eighty":-17.045645,"marketCap":1169794078},{"date":"2025-03-21","current":-10.235281,"twenty":-25.609403,"median":-21.417887,"eighty":-16.960589,"marketCap":1254088063},{"date":"2025-03-28","current":-9.33203,"twenty":-25.527539,"median":-21.321628,"eighty":-16.93886,"marketCap":1143416369},{"date":"2025-04-04","current":-7.64253,"twenty":-25.480594,"median":-21.202701,"eighty":-16.831205,"marketCap":936408691},{"date":"2025-04-11","current":-7.043483,"twenty":-25.340669,"median":-21.061141,"eighty":-16.666093,"marketCap":863009847},{"date":"2025-04-17","current":-8.672143,"twenty":-25.329214,"median":-21.042579,"eighty":-16.563339,"marketCap":1062562954},{"date":"2025-04-25","current":-11.068331,"twenty":-25.25285,"median":-20.951128,"eighty":-16.426861,"marketCap":1356158331},{"date":"2025-05-02","current":-12.790591,"twenty":-25.171712,"median":-20.933479,"eighty":-16.305436,"marketCap":1567180008},{"date":"2025-05-09","current":-12.551909,"twenty":-25.070517,"median":-20.891345,"eighty":-16.181125,"marketCap":1537935156},{"date":"2025-05-16","current":-9.774326,"twenty":-25.068859,"median":-20.829252,"eighty":-16.056814,"marketCap":1400885752},{"date":"2025-05-23","current":-9.895696,"twenty":-25.0453,"median":-20.693431,"eighty":-15.839386,"marketCap":1418280862},{"date":"2025-05-30","current":-9.000467,"twenty":-25.01052,"median":-20.672234,"eighty":-15.745511,"marketCap":1289973912},{"date":"2025-06-06","current":-8.619091,"twenty":-25.001825,"median":-20.550917,"eighty":-15.544032,"marketCap":1235314001},{"date":"2025-06-13","current":-8.920177,"twenty":-24.996225,"median":-20.487391,"eighty":-15.387426,"marketCap":1278466562},{"date":"2025-06-20","current":-8.679308,"twenty":-24.952868,"median":-20.449033,"eighty":-14.973238,"marketCap":1243944513},{"date":"2025-06-27","current":-8.462526,"twenty":-24.918331,"median":-20.434088,"eighty":-14.66039,"marketCap":1212874668},{"date":"2025-07-03","current":-8.175491,"twenty":-24.875783,"median":-20.408464,"eighty":-14.607558,"marketCap":1171735893},{"date":"2025-07-11","current":-7.587369,"twenty":-24.818526,"median":-20.385744,"eighty":-14.451133,"marketCap":1087444556},{"date":"2025-07-18","current":-7.840282,"twenty":-24.807686,"median":-20.281918,"eighty":-14.123781,"marketCap":1123692707},{"date":"2025-07-25","current":-7.334457,"twenty":-24.781668,"median":-20.180483,"eighty":-13.987039,"marketCap":1051196404},{"date":"2025-08-01","current":-7.145777,"twenty":-24.722332,"median":-20.085721,"eighty":-13.108576,"marketCap":1024154132},{"date":"2025-08-08","current":-5.211405,"twenty":-24.651853,"median":-19.971704,"eighty":-12.812535,"marketCap":932580977},{"date":"2025-08-15","current":-5.964179,"twenty":-24.61951,"median":-19.937893,"eighty":-12.626872,"marketCap":1067289809},{"date":"2025-08-22","current":-6.234546,"twenty":-24.540145,"median":-19.829477,"eighty":-12.490132,"marketCap":1115672078},{"date":"2025-08-29","current":-6.160517,"twenty":-24.4698,"median":-19.66456,"eighty":-12.119485,"marketCap":1102424552},{"date":"2025-09-05","current":-6.360074,"twenty":-24.389808,"median":-19.576169,"eighty":-11.77845,"marketCap":1138135274},{"date":"2025-09-12","current":-6.720564,"twenty":-24.139365,"median":-19.456275,"eighty":-11.057099,"marketCap":1202644966},{"date":"2025-09-19","current":-7.47695,"twenty":-24.11098,"median":-19.134734,"eighty":-10.896967,"marketCap":1338000122},{"date":"2025-09-26","current":-8.043434,"twenty":-24.072254,"median":-19.014985,"eighty":-10.567565,"marketCap":1439372495},{"date":"2025-10-03","current":-8.568076,"twenty":-24.020356,"median":-18.941828,"eighty":-10.325716,"marketCap":1533257136},{"date":"2025-10-10","current":-9.833009,"twenty":-23.986828,"median":-18.81071,"eighty":-10.186609,"marketCap":1759617036},{"date":"2025-10-17","current":-8.87063,"twenty":-23.947347,"median":-18.74276,"eighty":-9.917033,"marketCap":1587399198},{"date":"2025-10-24","current":-8.548764,"twenty":-23.914099,"median":-18.661907,"eighty":-9.852324,"marketCap":1529801259},{"date":"2025-10-31","current":-10.370526,"twenty":-23.886602,"median":-18.351918,"eighty":-9.836476,"marketCap":1855805594},{"date":"2025-11-07","current":-10.772858,"twenty":-23.868757,"median":-18.327399,"eighty":-9.850579,"marketCap":1927803018},{"date":"2025-11-14","current":-10.08006,"twenty":-23.852048,"median":-18.288418,"eighty":-9.817863,"marketCap":2123717400},{"date":"2025-11-21","current":-9.889979,"twenty":-23.841601,"median":-18.256152,"eighty":-9.836476,"marketCap":2083670157},{"date":"2025-11-28","current":-10.313341,"twenty":-23.799814,"median":-18.097181,"eighty":-9.841018,"marketCap":2172866288},{"date":"2025-12-05","current":-9.460856,"twenty":-23.776121,"median":-18.070517,"eighty":-9.814076,"marketCap":1993260474},{"date":"2025-12-12","current":-19.422835,"twenty":-23.650834,"median":-18.082412,"eighty":-9.833009,"marketCap":4092100041},{"date":"2025-12-19","current":-17.985707,"twenty":-23.62393,"median":-18.070517,"eighty":-9.841018,"marketCap":3789318618},{"date":"2025-12-26","current":-22.869735,"twenty":-23.621272,"median":-18.100056,"eighty":-9.848479,"marketCap":4818310220},{"date":"2026-01-02","current":-22.823793,"twenty":-23.615623,"median":-18.255492,"eighty":-9.851048,"marketCap":4808630734},{"date":"2026-01-09","current":-21.980412,"twenty":-23.576442,"median":-18.281194,"eighty":-9.851517,"marketCap":4630943013},{"date":"2026-01-16","current":-27.900487,"twenty":-23.621936,"median":-18.326514,"eighty":-9.853937,"marketCap":5878214018},{"date":"2026-01-23","current":-30.148409,"twenty":-23.790337,"median":-18.349084,"eighty":-9.86147,"marketCap":6351817477},{"date":"2026-01-30","current":-28.599475,"twenty":-23.883185,"median":-18.63625,"eighty":-9.874048,"marketCap":6025480495},{"date":"2026-02-06","current":-24.024872,"twenty":-24.012922,"median":-18.680713,"eighty":-9.881446,"marketCap":5061680173},{"date":"2026-02-13","current":-23.64092,"twenty":-24.104146,"median":-18.735704,"eighty":-9.886523,"marketCap":4980787319},{"date":"2026-02-20","current":-22.141212,"twenty":-24.072254,"median":-18.787312,"eighty":-9.891122,"marketCap":4664821216},{"date":"2026-02-27","current":-21.248606,"twenty":-24.026331,"median":-18.905431,"eighty":-9.903769,"marketCap":4476762617},{"date":"2026-03-06","current":-29.951815,"twenty":-24.389808,"median":-18.958825,"eighty":-9.939515,"marketCap":4229256176},{"date":"2026-03-13","current":-27.383083,"twenty":-24.63457,"median":-19.091174,"eighty":-9.953915,"marketCap":3866546098},{"date":"2026-03-20","current":-25.316057,"twenty":-24.813106,"median":-19.247915,"eighty":-9.965451,"marketCap":3574677833},{"date":"2026-03-27","current":-23.178791,"twenty":-24.786548,"median":-19.412443,"eighty":-10.00684,"marketCap":3272891714},{"date":"2026-04-02","current":-25.170562,"twenty":-24.791427,"median":-19.500107,"eighty":-10.024679,"marketCap":3554133708},{"date":"2026-04-10","current":-27.664038,"twenty":-24.924896,"median":-19.588971,"eighty":-10.070397,"marketCap":3906217513},{"date":"2026-04-17","current":-26.841241,"twenty":-25.001825,"median":-19.762743,"eighty":-10.08006,"marketCap":3790036942},{"date":"2026-04-24","current":-23.59019,"twenty":-25.001825,"median":-19.852578,"eighty":-10.16646,"marketCap":3330982000},{"date":"2026-05-01","current":-20.863024,"twenty":-25.001825,"median":-19.937893,"eighty":-10.183801,"marketCap":2945900742},{"date":"2026-05-08","current":-19.705365,"twenty":-24.994825,"median":-19.961493,"eighty":-10.197841,"marketCap":2782437010},{"date":"2026-05-15","current":-16.62279,"twenty":-24.933886,"median":-19.910742,"eighty":-10.230435,"marketCap":2831476129},{"date":"2026-05-22","current":-16.184689,"twenty":-24.924896,"median":-19.829477,"eighty":-10.235281,"marketCap":2756851382},{"date":"2026-05-29","current":-20.218762,"twenty":-24.916142,"median":-19.78569,"eighty":-10.28472,"marketCap":2854929621},{"date":"2026-06-05","current":-19.660066,"twenty":-24.837612,"median":-19.705365,"eighty":-10.310089,"marketCap":2776040603},{"date":"2026-06-12","current":-21.794185,"twenty":-24.818526,"median":-19.734054,"eighty":-10.313341,"marketCap":3077382440},{"date":"2026-06-18","current":-18.776621,"twenty":-24.802267,"median":-19.684963,"eighty":-10.332349,"marketCap":3198353220},{"date":"2026-06-26","current":-20.13271,"twenty":-24.776789,"median":-19.66456,"eighty":-10.358393,"marketCap":3429345397},{"date":"2026-07-02","current":-21.747499,"twenty":-24.722332,"median":-19.762743,"eighty":-10.368595,"marketCap":3704403773},{"date":"2026-07-10","current":-23.007619,"twenty":-24.651853,"median":-19.829477,"eighty":-10.39842,"marketCap":3919048812},{"date":"2026-07-17","current":-19.206397,"twenty":-24.633491,"median":-19.854838,"eighty":-10.468301,"marketCap":3271559971},{"date":"2026-07-24","current":-21.196718,"twenty":-24.602614,"median":-19.924318,"eighty":-10.512193,"marketCap":3610585412},{"date":"2026-07-31","current":-20.641765,"twenty":-24.584569,"median":-19.948142,"eighty":-10.52082,"marketCap":3516056306},{"date":"2026-08-07","current":-21.956128,"twenty":-24.559431,"median":-19.978813,"eighty":-10.545017,"marketCap":3739941031},{"date":"2026-08-14","current":-18.156488,"twenty":-24.476043,"median":-19.948142,"eighty":-10.550775,"marketCap":3900649177},{"date":"2026-08-21","current":-16.769027,"twenty":-24.436431,"median":-19.854838,"eighty":-10.567565,"marketCap":3602573975},{"date":"2026-08-24","current":-16.29437,"twenty":-24.42179,"median":-19.852578,"eighty":-10.572245,"marketCap":3500600880}],"updateTime":1787673759255},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GPCR\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1164246465","title":"新聞稿：Septerna任命資深行業專家Rajiv Patni醫學博士擔任首席醫療官","url":"https://stock-news.laohu8.com/highlight/detail?id=1164246465","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164246465?lang=zh_tw&edition=fundamental","pubTime":"2026-08-25 20:05","pubTimestamp":1787659519,"startTime":"0","endTime":"0","summary":"南旧金山，2026年8月25日——Septerna, Inc.，一家致力于开创G蛋白偶联受体药物发现新纪元的临床阶段生物技术公司，今日宣布任命Rajiv Patni医学博士为首席医疗官。Patni博士是一位兼具医师与科学家身份的生物制药高管，拥有超过25年领导研发、监管及医学事务组织的丰富经验。“在我的职业生涯中，我多次在研发轨迹的转折点加入公司，而Septerna正处在这一阶段，”Patni博士表示。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4599","GPCR","SEPN","R","BK4232","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649939231","title":"數據簡報-隨着小型企業不斷湧現，減肥藥的上市競爭日益白熱化","url":"https://stock-news.laohu8.com/highlight/detail?id=2649939231","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649939231?lang=zh_tw&edition=fundamental","pubTime":"2026-07-08 00:13","pubTimestamp":1783440834,"startTime":"0","endTime":"0","summary":"数据简报-随着小型企业不断涌现，减肥药的上市竞争日益白热化在第1、2和25段中补充了Kailera Therapeutics公司肥胖症药物的详细信息路透7月7日-凯莱拉制药的KLRA.O口服减肥药在中国开展的一项晚期临床试验中，帮助患者在第44周时减重 ，最高可达体重的10.9%。这两种药物目前均处于临床前试验阶段。华东制药中国华东制药公司的口服减肥候选药物HDM1002，在中国针对超重或肥胖受试者进行的一项早期研究中，使体重最多减少了6.8%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nL4T4391IA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1868836591.USD","SG9999013999.USD","IE00B19Z3581.USD","LU2108987350.USD","LU1551013342.USD","LU1712237335.SGD","LU2112291526.USD","LU0109394709.USD","LU2089283258.USD","LU2491049909.HKD","KLRA","LU1923622614.USD","IE00BK4W5L77.USD","LU2023250330.USD","BK4592","LU1162221912.USD","LU1934455194.USD","LU1430594728.SGD","LU2125909247.SGD","LLYX","LU2237443549.SGD","LU0323591593.USD","IE00B4R5TH58.HKD","01672","LU0158827948.USD","SG9999015341.SGD","LU0306806265.USD","LU1883839398.USD","LU1720051017.SGD","LU0133085943.USD","LU2097828557.USD","SGXZ31699556.SGD","LU0353189763.USD","GB00BDT5M118.USD","BK4532","LU1037948541.HKD","LU0353189680.USD","LU0265550946.USD","LU0466842654.USD","LU0225284248.USD","IE00B3T34201.USD","LU0006306889.USD","LU0211331839.USD","LU2461242641.AUD","03692","LU0256863811.USD","PFE","IE0004445015.USD","SG9999015978.USD","LU0417517546.SGD","LU0820561909.HKD","SG9999015358.SGD","LU2746668974.SGD","LU0683600562.USD","AZNH","LU1035775433.USD","LU0079474960.USD","SG9999015945.SGD","LU2552382132.HKD","SG9999003800.SGD","PPH","LU1280957306.USD","LU2552382058.USD","LU2750360997.AUD","LU1868836914.USD","MEDX","IE00BFSS7M15.SGD","LU1201861249.SGD","LU1291159041.SGD","LU2237443895.HKD","LU2360106947.USD","LU1868837300.USD","LU2596442595.SGD","SG9999011175.SGD","LU1069347547.HKD","LU2456880835.USD","FTXH","LU0321505439.SGD","LU0225771236.USD","LU2357305700.SGD","LU2023250843.SGD","LU0114720955.EUR","LU1969619763.USD","IE00BLSP4452.SGD","PJP","LU2106854487.HKD","LU0672654240.SGD","LU0198837287.USD","IHE","IE0002270589.USD","LU2111349929.HKD","VHT","LLII","LU2471134879.HKD","LU2471134796.USD","THNR","LU2360032135.SGD","IE00BJLML261.HKD","LU1232071149.USD","SG9999014914.USD","IE00BSNM7G36.USD","LU0942090050.USD","LU1093756168.USD","LU0266013472.USD","LU2242644610.SGD","IE00BLSP4239.USD","LU1571399168.USD","BK4007","LU1934455863.HKD","BK4139","LU0061475181.USD","LU1093756325.SGD","PAWZ","SGXZ57979304.SGD","LU0965509283.SGD","LU0265550359.USD","LU2265009873.SGD","LU2237443465.HKD","LU2417539215.USD","SG9999014880.SGD","LU2491050071.SGD","BK1589","LU0868494708.USD","LU2271345857.HKD","LU0289739699.SGD","IE0009355771.USD","BK4599","LU0786609619.USD","LU1814569148.SGD","LU1267930730.SGD","01801","LU2023250504.SGD","LU1699723380.USD","LU0154236417.USD","LU2168564149.EUR","LU0345770308.USD","LU0861579265.USD","BK4568","LU1941712264.USD","LU0943347566.SGD","LU0029864427.USD","LU0882574139.USD","LU0985481810.HKD","LU0965508806.USD","BK1161","LU0158827781.USD","JDOC","LU0210536198.USD","LU1066051225.USD","SG9999014906.USD","IE00B7KXQ091.USD","SG9999014567.USD","LU1929549753.HKD","LU0640476718.USD","VKTX","SG9999014559.SGD","LU1037948897.HKD","BK4550","IE0004445239.USD","IE00BWXC8680.SGD","LU0456855351.SGD","LU0965509101.SGD","LU2236285917.USD","LU2491050154.USD","LU2896262040.SGD","LU0130102774.USD","LU0225283273.USD","LU1061106388.HKD","BK4559","LU1804176565.USD","LU2328871848.SGD","LU1057294990.SGD","LU0208291251.USD","LU2756315664.SGD","LU0238689110.USD","IE00B4JS1V06.HKD","SG9999018857.SGD","HRTS","LU0130517989.USD","SG9999001176.USD","SGXZ99366536.SGD","LU2237443382.USD","ELIL","BK4534","LU0648001328.SGD","LU1551013425.SGD","LU0889565916.HKD","LU2023251221.USD","LU0868494617.USD","LU2433249047.HKD","LU1323610961.USD","IE00B19Z3B42.SGD","LU1983299246.USD","LU0096364046.USD","LU0320765992.SGD","LU0256863902.USD","LU1116320901.HKD","SGXZ51526630.SGD","LU0310800379.SGD","LU2264538146.SGD","ELIS","NVOX","LU2028103732.USD","LU0203347892.USD","MEDI","LU0980610538.SGD","LU1267930573.SGD","LLY","LU0820562030.AUD","SG9999018865.SGD","LU2237443622.USD","CURE","NVO","GPCR","LU2097828474.EUR","LU2087625088.SGD","LU0320765059.SGD","LU0203201768.USD","LU1941712348.USD","IE00BJJMRY28.SGD","SG9999002232.USD","LU0882574055.USD","GDOC","IXJ","LU0385154629.USD","RXL","SGXZ81514606.USD","LU2602419157.SGD","LU0689472784.USD","SG9999017495.SGD","LU0708995401.HKD","LU0477156953.USD","LU1035773651.USD","LU1127390331.HKD","IE00BFSS8Q28.SGD","LU2237438978.USD","LU2361045086.USD","LU1066053197.SGD","LU0203202063.USD","LU1934455277.USD","IE00B1BXHZ80.USD","IE0001KFT4U8.USD","LU0965509010.AUD","LU2746668461.USD","LU0321505868.SGD","BK1515","LU1116320737.USD","LU2213496289.HKD","SG9999014575.USD","LU2168564495.EUR","LU0106261372.USD","LU0985320562.USD","CANC","IE00BZ1G4Q59.USD","LU0964807845.USD","BK1574","LU0128525929.USD","NVOH","SG9999002224.SGD","AZN","IE00BKDWB100.SGD","BK4581","LU0097036916.USD","IE00BJJMRX11.SGD","SG9999015986.USD","SG9999001176.SGD","BK1583","IYH","LU0471298777.SGD","LU0122379950.USD","LU0471298694.HKD","LU0354030438.USD","LU0320765646.SGD","LLYZ","IE00B1XK9C88.USD","LU0320765489.SGD","LU1064131342.USD","LU0094547139.USD","LU2462157665.USD","LU1585245621.USD","LU1145028129.USD","LU1917777945.USD","IE00BKVL7J92.USD","LU1066051811.HKD","LU0823434740.USD","LU1989772840.SGD","LU2361044865.SGD","IE00BFTCPJ56.SGD","LU0455707207.USD","LU0432979614.USD","LU0859254822.USD","FHLC","OZEM","SG9999001440.SGD","IE00BBT3K403.USD","LU1894683348.USD","LU2125909593.SGD","LU2089984988.USD","LU0787776722.HKD","LU2125154935.USD","BK1191","LU2471134952.CNY","SG9999014898.SGD","BMED","MRK","LU0098860793.USD","IE00BN29S564.USD","IE00BKPKM429.USD","SG9999015952.SGD","LU1548497426.USD","LU1894683264.USD","IE00BK4W5M84.HKD","LU1989771016.USD","LU2089284900.SGD","LU2357627491.SGD","XLV","LU1868836757.USD","LU0170899867.USD","BK4588","LU0354030511.USD","LU2097828631.EUR","LU1623119135.USD","LU1366192091.USD","LU0820561818.USD","LU0823434583.USD","BK4585","BK4516","LU2168563687.JPY","LU1868837136.USD","LU0234572021.USD","LU2552382215.SGD","IE0002141913.USD","HK0000165453.HKD","IE00BJJMRZ35.SGD","LU2168564065.EUR","LU2471134523.USD","LU2488822045.USD","LU1988902786.USD","WDNA","LU2361044949.HKD","LU0316494557.USD","LU1989772923.USD","KURE","LU0345770993.USD","LU0203345920.USD","SG9999014542.SGD","IE00B775H168.HKD","LU2168564222.USD","BK4533","LU2063271972.USD","LU1829250122.USD","IE00B2B36J28.USD","LU2324357040.USD","LU0306807586.USD","LU0058720904.USD","LU2756315318.SGD","IE00BN8TJ469.HKD","LU0502904849.HKD","AGNG","LU2097828714.EUR","IE000M9KFDE8.USD","LU2237443978.SGD","LU2468319806.SGD","LU0708994859.HKD","ILDR","LU1023059063.AUD","LU2097828805.USD","LU1974910355.USD","LU0823416689.USD","LU2211815571.USD","IE00BJT1NW94.SGD","LU1066051498.USD","IE0005OL40V9.USD","LU2125154778.USD","LU0070302665.USD","LU1720051108.HKD","LU1069344957.HKD","LU2750360641.GBP","LU1629891620.HKD","LU0109391861.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642495621","title":"晶泰控股(02228)與國際知名藥企達成超4億美元AI藥物發現戰略合作 攻堅GPCR靶點口服新藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2642495621","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642495621?lang=zh_tw&edition=fundamental","pubTime":"2026-06-09 22:30","pubTimestamp":1781015452,"startTime":"0","endTime":"0","summary":"智通财经APP讯，晶泰控股 发布公告，公司董事会欣然宣布与一家国际知名生物制药公司达成战略合作。根据协议，合作方将向晶泰支付首付款并承担所有的早期研发费用，晶泰还将获得临床前、临床及商业化里程碑付款，以及未来的销售分成，项目潜在总金额超4亿美元。进入全面合作阶段后，晶泰将全面启用其结构理性药物设计平台。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452260.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AIPO","ARTY","BK1617","AGIX","BK4599","02228","GPCR","BK1141","BK4007","CHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641112886","title":"Structure實驗性減肥藥未顯示肝損傷跡象","url":"https://stock-news.laohu8.com/highlight/detail?id=2641112886","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641112886?lang=zh_tw&edition=fundamental","pubTime":"2026-06-06 05:15","pubTimestamp":1780694132,"startTime":"0","endTime":"0","summary":"Structure实验性减肥药未显示肝损伤迹象Sriparna Roy路透6月5日 - Structure Therapeutics周五表示，其试验性GLP-1减肥药未显示任何药物性肝损伤的迹象，且患者即使在服用较低剂量时仍持续减重。Structure公司今年3月曾报告，在一项中期试验中，服用该公司每日一次药片的患者，在44周后，180毫克剂量组的体重较安慰剂组最多减轻了39磅。Structure公司表示，对研究期间每位患者用药情况的回顾显示，虽然部分患者需要中断或减少剂量，但一旦恢复治疗或再次增加剂量，呕吐症状很少复发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nL4T42D1NS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","GPCR","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180747442","title":"Structure Therapeutics宣佈，Aleniglipron在2B期試驗中顯示出長達36周以上最高達16.2%的減重效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1180747442","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180747442?lang=zh_tw&edition=fundamental","pubTime":"2026-06-06 04:18","pubTimestamp":1780690711,"startTime":"0","endTime":"0","summary":"Structure Therapeutics Inc.  近日公布了其口服GLP-1受体激动剂Aleniglipron在2B期临床试验中的积极顶线结果。数据显示，在为期36周的治疗期内，接受Aleniglipron治疗的患者实现了显著的体重减轻，最高减重幅度达到16.2%。这项随机、双盲、安慰剂对照的试验评估了不同剂量Aleniglipron在肥胖或超重成人中的疗效与安全性。除了显著的减重数据，Aleniglipron在改善血糖控制等次要终点上也表现出积极趋势。这一积极数据进一步验证了Aleniglipron作为潜在重磅口服减肥疗法的前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","GPCR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178081119","title":"Structure Therapeutics旗下阿倫利普隆展現良好耐受性，停藥率僅為10.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1178081119","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178081119?lang=zh_tw&edition=fundamental","pubTime":"2026-06-06 04:18","pubTimestamp":1780690707,"startTime":"0","endTime":"0","summary":"Structure Therapeutics公司宣布，其研发的药物阿伦利普隆在临床试验中表现出良好的耐受性特征，患者停药率低至10.4%。这一数据突显了该药物在治疗过程中的可接受性与安全性，为其进一步的临床开发与应用奠定了积极基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","BK4599","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154055283","title":"Structure Therapeutics修訂並重述與Leerink Partners及Cantor Fitzgerald的銷售協議","url":"https://stock-news.laohu8.com/highlight/detail?id=1154055283","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154055283?lang=zh_tw&edition=fundamental","pubTime":"2026-05-08 05:17","pubTimestamp":1778188666,"startTime":"0","endTime":"0","summary":"生物制药公司Structure Therapeutics Inc于2026年5月7日向美国证券交易委员会提交文件，宣布与Leerink Partners LLC及Cantor Fitzgerald & Co.共同签署经修订与重述的股权分销协议。该协议旨在优化公司未来通过\"at-the-market\"股权发行计划进行融资的运作框架。此次协议修订涉及分销条款、佣金结构及结算流程等核心商业条款的更新，标志着Structure Therapeutics与两家顶尖医疗健康领域投行深化战略合作的里程碑。通过完善销售协议机制，公司将进一步增强资本运作灵活性，为管线药物研发提供可持续的资金支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","GPCR","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160867102","title":"Structure Therapeutics將ATM增發規模擴大1.5億美元 總額達4億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1160867102","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160867102?lang=zh_tw&edition=fundamental","pubTime":"2026-05-08 05:17","pubTimestamp":1778188634,"startTime":"0","endTime":"0","summary":"生物医药公司Structure Therapeutics Inc（股票代码：GPCR）近日向美国证券交易委员会提交文件，宣布将其ATM（按市价发行）股票增发计划规模扩大1.5亿美元。此次调整后，该公司的ATM增发总规模将达到4亿美元。\nATM增发机制允许上市公司在特定时期内，根据市场情况灵活地向公众发售新股。此次规模扩充将为Structure Therapeutics提供更充足的资金流动性，支持其临床阶段药物研发管线的推进。该公司专注于开发针对代谢性疾病的口服小分子疗法，此次融资安排彰显了其持续优化资本结构的战略布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","BK4007","GPCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630391708","title":"埃諾格魯肽注射液全國首批處方落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2630391708","media":"经济参考网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630391708?lang=zh_tw&edition=fundamental","pubTime":"2026-04-27 20:50","pubTimestamp":1777294212,"startTime":"0","endTime":"0","summary":"4月27日，新一代cAMP偏向型GLP-1受体激动剂埃诺格鲁肽注射液（先维盈）在北京大学人民医院与复旦大学附属中山医院同步开出全国首批处方，标志着这款创新体重管理疗法正式在中国迈入临床应用阶段。据悉，GLP-1受体激动剂的创新研发有两条路线。传统路线是以GLP-1为核心靶点叠加其他作用靶点，如GIP、GCG等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604273720616957.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604273720616957.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4007","GPCR","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115849765","title":"Structure Therapeutics任命Matthew Lang為首席運營官兼總法律顧問","url":"https://stock-news.laohu8.com/highlight/detail?id=1115849765","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115849765?lang=zh_tw&edition=fundamental","pubTime":"2026-04-15 04:07","pubTimestamp":1776197275,"startTime":"0","endTime":"0","summary":"旧金山，2026年4月14日——临床阶段全球生物制药公司Structure Therapeutics Inc.今日宣布，任命Matthew Lang, J.D. 为公司首席运营官兼总法律顾问。Lang先生在加入Structure Therapeutics时，已在全球生物制药机构拥有超过十五年的高管领导经验，其深厚专长涵盖法律、企业战略、合规、风险管理和业务发展等多个领域。Structure Therapeutics首席执行官Raymond Stevens博士表示：\"Matt是一位经验丰富的领导者，在引导组织实现增长和转型方面拥有卓越的业绩记录。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4232","BK4599","GPCR","R","LENZ","BK4539","BK4022","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624683807","title":"BUZZ-H.C. Wainwright表示，禮來肥胖藥獲批為Structure公司的藥物創造了機會","url":"https://stock-news.laohu8.com/highlight/detail?id=2624683807","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624683807?lang=zh_tw&edition=fundamental","pubTime":"2026-04-02 23:57","pubTimestamp":1775145467,"startTime":"0","endTime":"0","summary":"4月2日 - ** H.C. Wainwright称礼来公司的Foundayo  获得FDA批准是药物开发商Structure Therapeutics公司GPCR.O口服肥胖症项目的积极进展** 经纪公司维持GPCR股票的 \"买入 \"评级，目标价100美元。** H.C. Wainwright 说：\"我们认为 aleniglipron 是一种比 Foundayo 更具吸引力的降阶维持选择，因为从 Zepbound 或 Wegovy 转药的患者服用 16% 以上药物的反弹可能会大大低于服用 12% 药物的反弹\"。** 称礼来公司的药片定价较低，可以吸引更多患者，从而扩大口服肥胖症市场，如果 GPCR 的药片上市，这也会对其有所帮助。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nL4S40L1IA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","GPCR","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620476982","title":"美股異動 | 禮來(LLY.US)跌超4% 碩迪生物(GPCR.US)實驗性減肥藥公布積極數據","url":"https://stock-news.laohu8.com/highlight/detail?id=2620476982","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620476982?lang=zh_tw&edition=fundamental","pubTime":"2026-03-17 23:14","pubTimestamp":1773760452,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周二，礼来(LLY.US)股价低开低走，截至发稿，该股跌超4%，报948.76美元。消息面上，硕迪生物(GPCR.US)此前公布其实验性减肥药aleniglipron积极结果。数据显示，患者在服用44周后，体重减轻了约15%。BMO资本市场分析师Evan Seigerman指出，该药物的疗效“看起来极具竞争力”，甚至可能优于诺和诺德(NVO.US)和礼来的同类口服药。硕迪生物计划在2026年下半年启动后期研究，采用“低量且缓慢”的剂量滴定法以预防胃肠道副作用。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415150.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1069344957.HKD","LU2361044949.HKD","LU1804176565.USD","LU2237438978.USD","LU0820562030.AUD","LU2237443382.USD","LU2357305700.SGD","LU2491049909.HKD","BK4533","LU1145028129.USD","ELIL","LU2746668974.SGD","IE00B1XK9C88.USD","LU2168564149.EUR","LLYX","LU1720051108.HKD","IE00B1BXHZ80.USD","LU0882574055.USD","LU2456880835.USD","LU0672654240.SGD","IE00BK4W5L77.USD","LU0823416689.USD","LU0385154629.USD","SGXZ81514606.USD","LU1057294990.SGD","LU0353189763.USD","LU1868837136.USD","LU1551013342.USD","LU1712237335.SGD","LU2213496289.HKD","LU2087625088.SGD","LU2471134952.CNY","LU2324357040.USD","LU1232071149.USD","LU0354030438.USD","LU0256863811.USD","LU1093756325.SGD","SGXZ51526630.SGD","GPCR","LU1989771016.USD","LU2462157665.USD","LU2237443895.HKD","LU2756315664.SGD","IE00BKDWB100.SGD","LU0158827948.USD","LU2237443549.SGD","IE00BK4W5M84.HKD","LU2361045086.USD","LU0094547139.USD","LU1974910355.USD","LU0889565916.HKD","LU0096364046.USD","LU1548497426.USD","LU1983299246.USD","SG9999001176.SGD","LU2896262040.SGD","LU0122379950.USD","LU2168564222.USD","LU2491050154.USD","LU0061475181.USD","IE00BJJMRY28.SGD","LU0353189680.USD","LU2237443622.USD","LU2461242641.AUD","LU2360106947.USD","LU1917777945.USD","LU0456855351.SGD","LU0006306889.USD","SG9999014898.SGD","IE00BFSS7M15.SGD","BK4585","LU2111349929.HKD","LU0432979614.USD","LU1291159041.SGD","LU2602419157.SGD","IE0001KFT4U8.USD","LU0354030511.USD","SG9999018857.SGD","LU0316494557.USD","IE00B4JS1V06.HKD","IE00BFSS8Q28.SGD","LU2361044865.SGD","SGXZ31699556.SGD","LU0289739699.SGD","LU0683600562.USD","LU2471134796.USD","IE00BJJMRX11.SGD","LU2089284900.SGD","LU0109394709.USD","IE00BN29S564.USD","LU0471298694.HKD","BK4599","LU0320765059.SGD","LU0466842654.USD","SGXZ99366536.SGD","SG9999015952.SGD","LU0198837287.USD","LU2023251221.USD","BK4581","IE00BJT1NW94.SGD","LU2417539215.USD","LU2746668461.USD","LU0266013472.USD","LU2491050071.SGD","LU0210536198.USD","LU0256863902.USD","LU0158827781.USD","LU1280957306.USD","LU2271345857.HKD","LU0689472784.USD","LU1720051017.SGD","SG9999014880.SGD","LU0238689110.USD","SG9999015978.USD","LU2237443465.HKD","LU0708995401.HKD","LU0943347566.SGD","LU1868836757.USD","LU0114720955.EUR","LU0106261372.USD","LU0471298777.SGD","SG9999015986.USD","LU1267930730.SGD","LU2236285917.USD","LU0203202063.USD","LU2089984988.USD","LLY","IE00B775H168.HKD","IE00BFTCPJ56.SGD","LU2108987350.USD","LU0058720904.USD","SG9999018865.SGD","LU2468319806.SGD","LU2750360997.AUD","LU1988902786.USD","BK4534","LU0882574139.USD","LU2023250330.USD","LU0820561909.HKD","LU2168563687.JPY","LU2063271972.USD","LU2471134879.HKD","LU0823434740.USD","LU2756315318.SGD","IE0004445239.USD","LU0225283273.USD","LU2471134523.USD","LU0786609619.USD","SG9999014906.USD","LU0079474960.USD","LU2106854487.HKD","IE0009355771.USD","LU2211815571.USD","GB00BDT5M118.USD","LU1035775433.USD","LU2028103732.USD","LU1061106388.HKD","SG9999013999.USD","LU0320765992.SGD","SG9999015945.SGD","BK4007","IE00B7KXQ091.USD","SGXZ57979304.SGD","LU2265009873.SGD","LU0640476718.USD","LU2552382132.HKD","LU2023250504.SGD","LU2168564495.EUR","LU2089283258.USD","LU1064131342.USD","IE00BKPKM429.USD","IE0002141913.USD","LU1323610961.USD","IE00BJJMRZ35.SGD","LU0203201768.USD","ELIS","LU2168564065.EUR","LU2237443978.SGD","LU2264538146.SGD","SG9999017495.SGD","IE00BJLML261.HKD","LU1366192091.USD","LU2112291526.USD","LU0109391861.USD","SG9999001176.USD","LU0323591593.USD","LLII","IE0004445015.USD","LLYZ","LU0787776722.HKD","LU2750360641.GBP","LU2552382058.USD","LU1814569148.SGD","LU0097036916.USD","IE00B2B36J28.USD","LU1623119135.USD","IE00B4R5TH58.HKD","IE00BWXC8680.SGD","LU0234572021.USD","LU0417517546.SGD","BK4516","LU1868836591.USD","BK4588","LU1093756168.USD","LU1127390331.HKD","LU1868837300.USD","LU1551013425.SGD","LU2552382215.SGD","LU1868836914.USD","LU0964807845.USD","SG9999014914.USD","IE0005OL40V9.USD","LU0820561818.USD","LU1023059063.AUD","LU1629891620.HKD","LU0823434583.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620476890","title":"Structure肥胖藥物研究結果直追諾和諾德與禮來","url":"https://stock-news.laohu8.com/highlight/detail?id=2620476890","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620476890?lang=zh_tw&edition=fundamental","pubTime":"2026-03-17 23:08","pubTimestamp":1773760090,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2461242641.AUD","SG9999017495.SGD","LU0354030511.USD","SG9999014898.SGD","BK4534","IE00BJJMRY28.SGD","IE00BFTCPJ56.SGD","LU0689472784.USD","LU2471134952.CNY","LU1868836591.USD","LU2168564149.EUR","BK4588","LU0353189763.USD","LU0471298777.SGD","LU0203201768.USD","LU0466842654.USD","LU2468319806.SGD","LU2361045086.USD","LU2462157665.USD","IE00BKVL7J92.USD","LU0234572021.USD","LU1093756168.USD","LU1989771016.USD","BK4599","LU2028103732.USD","SG9999013999.USD","LU0079474960.USD","IE00BN29S564.USD","LU2237443978.SGD","LU0266013472.USD","LLYZ","LU2237443622.USD","LU1093756325.SGD","LU2456880835.USD","LU1280957306.USD","LU1323610961.USD","LU2746668974.SGD","LU2750360997.AUD","LU0225283273.USD","IE00BFSS8Q28.SGD","LU2023251221.USD","LU2237438978.USD","LU2168563687.JPY","ELIS","LU2236285917.USD","BK4516","LU0943347566.SGD","IE0004445239.USD","LU0006306889.USD","LU1720051017.SGD","SGXZ31699556.SGD","LU0198837287.USD","LU0203202063.USD","LU2089984988.USD","IE00B1BXHZ80.USD","LU1069344957.HKD","LU0708995401.HKD","LU1551013425.SGD","LU2111349929.HKD","GPCR","IE0001KFT4U8.USD","IE00BJJMRZ35.SGD","LU0316494557.USD","LU2112291526.USD","IE00B1XK9C88.USD","IE00BKDWB100.SGD","LU0889565916.HKD","LU1974910355.USD","IE00BJT1NW94.SGD","IE00BZ1G4Q59.USD","LU1057294990.SGD","LU0323591593.USD","LU1366192091.USD","LLYX","LU2552382132.HKD","LU2168564065.EUR","LU0964807845.USD","LU2023250330.USD","LU2264538146.SGD","LU1623119135.USD","LU2213496289.HKD","SG9999015952.SGD","LU2417539215.USD","IE00B775H168.HKD","LU0109394709.USD","LU2471134523.USD","LU2750360641.GBP","LU0256863811.USD","LU0158827781.USD","LU1145028129.USD","NVOX","LU0353189680.USD","LU0882574055.USD","LU1061106388.HKD","LU0672654240.SGD","LU0320765992.SGD","GB00BDT5M118.USD","LU2756315318.SGD","LU1064131342.USD","LU1868836757.USD","LU0786609619.USD","LU1868837300.USD","LU0114720955.EUR","LU2237443549.SGD","LU2324357040.USD","LU1291159041.SGD","LU1720051108.HKD","LU2491049909.HKD","LU2089284900.SGD","LU1804176565.USD","LU0106261372.USD","LU0094547139.USD","LU2168564495.EUR","LU0122379950.USD","BK4533","SG9999015978.USD","LU0823434583.USD","LU0109391861.USD","LU1267930730.SGD","SGXZ51526630.SGD","LU0823416689.USD","IE0009355771.USD","IE00BK4W5M84.HKD","SG9999018857.SGD","LU1917777945.USD","SGXZ99366536.SGD","LU2471134796.USD","LU0289739699.SGD","LU2896262040.SGD","LU0096364046.USD","LU0882574139.USD","IE00B7KXQ091.USD","IE0005OL40V9.USD","LU1629891620.HKD","LU2106854487.HKD","LU2063271972.USD","BK4007","LLII","IE00BJLML261.HKD","LU2746668461.USD","SGXZ57979304.SGD","LU0354030438.USD","SG9999018865.SGD","LU2360106947.USD","LU1548497426.USD","LU2089283258.USD","LU0238689110.USD","LU0683600562.USD","LU0787776722.HKD","LU2271345857.HKD","LU2237443465.HKD","LU0820562030.AUD","LU1868836914.USD","LU2491050071.SGD","LU2552382058.USD","SG9999001176.SGD","SG9999014906.USD","LU0058720904.USD","LU2602419157.SGD","LU2361044949.HKD","LU2552382215.SGD","BK4581","LU2087625088.SGD","SG9999014880.SGD","LU2237443382.USD","IE00B4JS1V06.HKD","LU1232071149.USD","LU2361044865.SGD","LU0158827948.USD","LU2108987350.USD","LU2023250504.SGD","SG9999001176.USD","IE0002141913.USD","LU0417517546.SGD","SG9999014914.USD","LU0320765059.SGD","LU1127390331.HKD","LU2237443895.HKD","LU2756315664.SGD","BK4532","LU0820561909.HKD","LU1551013342.USD","LU0456855351.SGD","LU0097036916.USD","LU2491050154.USD","ELIL","LU1814569148.SGD","IE00BKPKM429.USD","NVOH","SGXZ81514606.USD","LU0471298694.HKD","LU0061475181.USD","LU0256863902.USD","SG9999015986.USD","IE00B4R5TH58.HKD","LU0385154629.USD","LU1868837136.USD","LU2211815571.USD","LU0432979614.USD","LU2168564222.USD","LU0154236417.USD","LU1712237335.SGD","IE0004445015.USD","IE00B2B36J28.USD","IE00BFSS7M15.SGD","LU1023059063.AUD","LU0210536198.USD","LU2265009873.SGD","IE00BWXC8680.SGD","LU0640476718.USD","IE00BJJMRX11.SGD","LU0820561818.USD","BK4585","LU1035775433.USD","LU1988902786.USD","LU2357305700.SGD","SG9999015945.SGD","IE00BK4W5L77.USD","LU1983299246.USD","LU2471134879.HKD","LU0823434740.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140362721","title":"Structure Therapeutics股價上漲6% 公布實驗性肥胖症藥物中期試驗結果","url":"https://stock-news.laohu8.com/highlight/detail?id=1140362721","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140362721?lang=zh_tw&edition=fundamental","pubTime":"2026-03-16 21:32","pubTimestamp":1773667958,"startTime":"0","endTime":"0","summary":"在披露其实验性口服肥胖症药物的中期临床试验数据后，Structure Therapeutics Inc.（股票代码：GPCR）股价今日上涨6%。\n该公司公布的第二阶段研究结果显示，其口服GLP-1受体激动剂GSBR-1292在12周治疗期内展现出显著的减重效果。接受治疗的患者平均体重下降幅度达统计学意义，且药物耐受性良好，未出现严重不良反应。\n这一积极数据令投资者对该公司挑战诺和诺德、礼来等制药巨头的口服减肥药市场前景感到乐观。分析师指出，若后续临床试验继续验证其疗效与安全性，该药物有望成为肥胖症治疗领域的重要竞争者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4599","GPCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134097930","title":"Structure Therapeutics股價逆轉走勢 披露中期試驗結果後盤前大漲13.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1134097930","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134097930?lang=zh_tw&edition=fundamental","pubTime":"2026-03-16 19:24","pubTimestamp":1773660253,"startTime":"0","endTime":"0","summary":"在公布其实验性肥胖症药物的中期临床试验结果后，Structure Therapeutics的股价出现显著逆转。该股在盘前交易中一度飙升13.5%，扭转了此前的下跌趋势。\n此次披露的积极数据主要涉及公司研发的口服肥胖症疗法，该疗法在中期试验中达到了主要终点和关键次要终点，显示出显著的减重效果和良好的安全性特征。这一利好消息提振了投资者信心，推动股价强势反弹。\n市场分析师认为，这一进展不仅验证了该药物的潜力，也为Structure Therapeutics在竞争激烈的减肥药市场中赢得了重要地位。随着肥胖症治疗需求的持续增长，该公司的未来发展前景备受关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","GPCR","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160730772","title":"Structure Therapeutics盤前跌1.6% 披露實驗性減肥藥中期試驗結果","url":"https://stock-news.laohu8.com/highlight/detail?id=1160730772","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160730772?lang=zh_tw&edition=fundamental","pubTime":"2026-03-16 19:11","pubTimestamp":1773659469,"startTime":"0","endTime":"0","summary":"在公布其实验性口服减肥药物的中期临床试验数据后，生物制药公司Structure Therapeutics的股价在盘前交易时段下跌1.6%。此次下跌反映了市场对该阶段性成果的初步反应。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","BK4599","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619452444","title":"研究顯示，結構公司的肥胖藥片最多可減輕 16.3% 的體重","url":"https://stock-news.laohu8.com/highlight/detail?id=2619452444","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619452444?lang=zh_tw&edition=fundamental","pubTime":"2026-03-16 19:04","pubTimestamp":1773659060,"startTime":"0","endTime":"0","summary":"研究显示，结构公司的肥胖药片最多可减轻 16.3% 的体重路透3月16日 - Structure Therapeutics GPCR.O称，在一项中期研究中，其口服肥胖症药物aleniglipron与安慰剂相比，经过44周的治疗后，体重减轻达16.3%。(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nL4S4040WF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4599","GPCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175317698","title":"Structure Therapeutics公司：FDA二期結束會議定於2026年第二季度；三期試驗啓動計劃於2026年下半年推進","url":"https://stock-news.laohu8.com/highlight/detail?id=1175317698","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175317698?lang=zh_tw&edition=fundamental","pubTime":"2026-03-16 19:04","pubTimestamp":1773659040,"startTime":"0","endTime":"0","summary":"Structure Therapeutics公司宣布，其与美国食品药品监督管理局（FDA）的二期临床试验结束会议已正式安排在2026年第二季度举行。此次会议旨在讨论二期试验数据，并为后续的三期临床试验方案提供指导。\n与此同时，公司确认其三期临床试验的启动计划仍按原定时间表推进，预计将在2026年下半年开始。这一进展标志着公司在核心研发项目上迈出了关键一步，为其主要候选药物的未来发展奠定了重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4599","GPCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144091293","title":"Structure Therapeutics中期數據：2.5毫克起始劑量組不良事件相關停藥率為2.0%-3.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1144091293","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144091293?lang=zh_tw&edition=fundamental","pubTime":"2026-03-16 19:03","pubTimestamp":1773659032,"startTime":"0","endTime":"0","summary":"STRUCTURE THERAPEUTICS INC最新公布的中期临床试验数据显示，采用2.5毫克起始剂量的治疗组中，因不良事件导致停药的发生率介于2.0%至3.4%之间。这一关键指标为评估该药物安全性提供了重要参考。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","BK4007","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120934691","title":"Structure Therapeutics公布每日一次口服小分子GLP-1受體激動劑Aleniglipron二期臨床試驗積極頂線數據","url":"https://stock-news.laohu8.com/highlight/detail?id=1120934691","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120934691?lang=zh_tw&edition=fundamental","pubTime":"2026-03-16 19:01","pubTimestamp":1773658905,"startTime":"0","endTime":"0","summary":"STRUCTURE THERAPEUTICS INC（股票代码：GPCR）近日宣布，其研发的每日一次口服小分子GLP-1受体激动剂Aleniglipron，在二期ACCESS II临床试验中取得了积极的顶线数据。这一突破性进展标志着公司在代谢性疾病治疗领域迈出了重要一步。\n临床试验结果显示，Aleniglipron在有效性和安全性方面均表现出色，为后续研发奠定了坚实基础。该药物若成功上市，有望为全球数百万糖尿病患者提供更便捷的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","GPCR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":23,"code":"91000000","status":"200"}]}}